UCB to divest mature neurology and allergy portfolio in China for $680m to CBC Group and Mubadala
UCB, a Belgian biopharmaceutical company, has announced the divestment of its mature neurology and allergy portfolio in China for $680 million, marking a strategic shift ... Read More
Shockwave through biotech: AN2 Therapeutics slashes workforce after trial fails
AN2 Therapeutics, Inc., a pioneering force in novel small molecule drugs, has announced a dramatic reduction of its workforce by approximately 50%. This decision follows ... Read More
Antengene’s XPOVIO approved in China for diffuse large B-cell lymphoma
Antengene Corporation Limited, a commercial-stage global biopharmaceutical company, has announced a significant milestone with the China National Medical Products Administration (NMPA) approving a new indication ... Read More
CASI Pharmaceuticals advances in kidney transplant treatment and explores strategic sale in China
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a notable player in the biopharmaceutical sector, has made a significant announcement that could have wide-reaching implications for kidney transplant ... Read More
Johnson & Johnson strikes $1.2bn deal with Numab Therapeutics for atopic dermatitis candidate
In a significant move to enhance its immunology offerings, Johnson & Johnson (NYSE: JNJ) has announced a definitive agreement to acquire a wholly-owned subsidiary of ... Read More
Biocon Biologics secures license agreement for biosimilar launch in US
In a landmark announcement, Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and a subsidiary of Biocon Ltd, revealed its settlement and license ... Read More